Skip to main content
Top
Published in: CNS Drugs 5/2019

01-05-2019 | Carbamazepine | Original Research Article

The Effect of Non-Gabapentinoid Anticonvulsants on Sensorimotor Recovery After Human Spinal Cord Injury

Authors: Freda M. Warner, Catherine R. Jutzeler, Jacquelyn J. Cragg, Bobo Tong, Lukas Grassner, Frank Bradke, Fred Geisler, John K. Kramer

Published in: CNS Drugs | Issue 5/2019

Login to get access

Abstract

Background

Recent observational studies have shown an association between gabapentinoid anticonvulsants and greater motor recovery after spinal cord injury. There is preclinical evidence to suggest that other anticonvulsants, such as sodium channel blockers, may also confer beneficial effects.

Purpose

The aim of the current study was to determine if non-gabapentinoid anticonvulsants were associated with neurological recovery after acute, traumatic spinal cord injury.

Methods

This was an observational cohort study using data from the Sygen clinical trial. The primary outcome was total motor score recovery in the first year after injury. Anticonvulsant use was extracted from concomitant medication records; individuals were classified based on early administration (within 30 days of injury), or late/no administration. Motor recovery was compared using linear mixed effects regression models with a drug-by-time interaction, and adjustment for confounders. A secondary analysis incorporated a propensity score matched cohort.

Results

Of the cohort (n = 570), 6% received anticonvulsants (carbamazepine, phenytoin, clonazepam, phenobarbital, and valproic acid) early after injury. After adjustments for initial injury level and severity, early exposure to non-gabapentinoid anticonvulsants was not associated with motor neurological outcomes (p = 0.38 for all anticonvulsants, p = 0.83 for sodium channel blockers, p = 0.82 in propensity-matched cohort).

Conclusion

Non-gabapentinoid anticonvulsant exposure was not associated with greater or lesser neurological recovery. This suggests that these medications, as administered for the acute management of spinal cord injury, do not impact long-term neurological outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord. 2007;45:190–205.CrossRefPubMed Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord. 2007;45:190–205.CrossRefPubMed
2.
go back to reference Reier PJ, Lane MA, Hall ED, Teng YD, Howland DR. Translational spinal cord injury research: preclinical guidelines and challenges. Handb Clin Neurol. 2012;109:411–33.CrossRefPubMedPubMedCentral Reier PJ, Lane MA, Hall ED, Teng YD, Howland DR. Translational spinal cord injury research: preclinical guidelines and challenges. Handb Clin Neurol. 2012;109:411–33.CrossRefPubMedPubMedCentral
3.
go back to reference Guy S, Mehta S, Leff L, Teasell R, Loh E. Anticonvulsant medication use for the management of pain following spinal cord injury: systematic review and effectiveness analysis. Spinal Cord. 2014;52:89–96.CrossRefPubMed Guy S, Mehta S, Leff L, Teasell R, Loh E. Anticonvulsant medication use for the management of pain following spinal cord injury: systematic review and effectiveness analysis. Spinal Cord. 2014;52:89–96.CrossRefPubMed
4.
go back to reference Kitzman P, Cecil D, Kolpek JH. The risks of polypharmacy following spinal cord injury. J Spinal Cord Med. 2014;0:1–7. Kitzman P, Cecil D, Kolpek JH. The risks of polypharmacy following spinal cord injury. J Spinal Cord Med. 2014;0:1–7.
5.
go back to reference Sitges M, Chiu LM, Reed RC. Effects of levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, oxcarbazepine, topiramate, vinpocetine and sertraline on presynaptic hippocampal Na(+) and Ca(2+) channels permeability. Neurochem Res. 2016;41:758–69.CrossRefPubMed Sitges M, Chiu LM, Reed RC. Effects of levetiracetam, carbamazepine, phenytoin, valproate, lamotrigine, oxcarbazepine, topiramate, vinpocetine and sertraline on presynaptic hippocampal Na(+) and Ca(2+) channels permeability. Neurochem Res. 2016;41:758–69.CrossRefPubMed
6.
go back to reference Tedeschi A, Dupraz S, Laskowski CJ, Beyer M, Schultze JL, Bradke F, et al. The calcium channel subunit Alpha2delta2 suppresses axon regeneration in the adult CNS. Neuron. 2016;92:419–434.CrossRefPubMed Tedeschi A, Dupraz S, Laskowski CJ, Beyer M, Schultze JL, Bradke F, et al. The calcium channel subunit Alpha2delta2 suppresses axon regeneration in the adult CNS. Neuron. 2016;92:419–434.CrossRefPubMed
7.
go back to reference Cragg JJ, Haefeli J, Jutzeler CR, Röhrich F, Weidner N, Saur M, et al. Effects of pain and pain management on motor recovery of spinal cord-injured patients: a longitudinal study. Neurorehabil Neural Repair. 2016;30:753–61.CrossRefPubMed Cragg JJ, Haefeli J, Jutzeler CR, Röhrich F, Weidner N, Saur M, et al. Effects of pain and pain management on motor recovery of spinal cord-injured patients: a longitudinal study. Neurorehabil Neural Repair. 2016;30:753–61.CrossRefPubMed
8.
go back to reference Warner FM, Cragg JJ, Jutzeler CR, Röhrich F, Weidner N, Saur M, et al. Early administration of gabapentinoids improves motor recovery after human spinal cord injury. Cell Rep. 2017;18:1614–8.CrossRefPubMed Warner FM, Cragg JJ, Jutzeler CR, Röhrich F, Weidner N, Saur M, et al. Early administration of gabapentinoids improves motor recovery after human spinal cord injury. Cell Rep. 2017;18:1614–8.CrossRefPubMed
9.
go back to reference Geisler FH, Coleman WP, Grieco G, Poonian D, Group SS. The Sygen multicenter acute spinal cord injury study. Spine (Phila Pa 1976). 2001;26:S87–98.CrossRef Geisler FH, Coleman WP, Grieco G, Poonian D, Group SS. The Sygen multicenter acute spinal cord injury study. Spine (Phila Pa 1976). 2001;26:S87–98.CrossRef
10.
go back to reference Kirshblum S, Waring W. Updates for the international standards for neurological classification of spinal cord injury. Phys Med Rehabil Clin N Am. 2014;25:505–17.CrossRefPubMed Kirshblum S, Waring W. Updates for the international standards for neurological classification of spinal cord injury. Phys Med Rehabil Clin N Am. 2014;25:505–17.CrossRefPubMed
11.
go back to reference Geisler FH, Coleman WP, Grieco G, Poonian D. Recruitment and early treatment in a multicenter study of acute spinal cord injury. Spine (Phila Pa 1976). 2001;26:S58–67.CrossRef Geisler FH, Coleman WP, Grieco G, Poonian D. Recruitment and early treatment in a multicenter study of acute spinal cord injury. Spine (Phila Pa 1976). 2001;26:S58–67.CrossRef
12.
go back to reference Bracken MB, Shepard MJ, Collins WF, Holford TR, Baskin DS, Eisenberg HM, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg. 1992;76:23–31.CrossRefPubMed Bracken MB, Shepard MJ, Collins WF, Holford TR, Baskin DS, Eisenberg HM, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study. J Neurosurg. 1992;76:23–31.CrossRefPubMed
13.
go back to reference Geisler FH, Coleman WP, Grieco G, Poonian D. Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine (Phila Pa 1976). 2001;15:S68–86.CrossRef Geisler FH, Coleman WP, Grieco G, Poonian D. Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine (Phila Pa 1976). 2001;15:S68–86.CrossRef
14.
go back to reference Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–82.CrossRefPubMed Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–82.CrossRefPubMed
16.
go back to reference Van Middendorp JJ, Hosman AJF, Pouw MH, Van De Meent H. Is determination between complete and incomplete traumatic spinal cord injury clinically relevant Validation of the ASIA sacral sparing criteria in a prospective cohort of 432 patients. Spinal Cord. 2009;47:809–16.CrossRefPubMed Van Middendorp JJ, Hosman AJF, Pouw MH, Van De Meent H. Is determination between complete and incomplete traumatic spinal cord injury clinically relevant Validation of the ASIA sacral sparing criteria in a prospective cohort of 432 patients. Spinal Cord. 2009;47:809–16.CrossRefPubMed
17.
go back to reference Dvorak MF, Noonan VK, Fallah N, Fisher CG, Rivers CS, Ahn H, et al. Minimizing errors in acute traumatic spinal cord injury trials by acknowledging the heterogeneity of spinal cord anatomy and injury severity: an observational Canadian cohort analysis. J Neurotrauma. 2014;31:1540–7.CrossRefPubMedPubMedCentral Dvorak MF, Noonan VK, Fallah N, Fisher CG, Rivers CS, Ahn H, et al. Minimizing errors in acute traumatic spinal cord injury trials by acknowledging the heterogeneity of spinal cord anatomy and injury severity: an observational Canadian cohort analysis. J Neurotrauma. 2014;31:1540–7.CrossRefPubMedPubMedCentral
18.
go back to reference Hains BC, Saab CY, Lo AC, Waxman SG. Sodium channel blockade with phenytoin protects spinal cord axons, enhances axonal conduction, and improves functional motor recovery after contusion SCI. Exp Neurol. 2004;188:365–77.CrossRefPubMed Hains BC, Saab CY, Lo AC, Waxman SG. Sodium channel blockade with phenytoin protects spinal cord axons, enhances axonal conduction, and improves functional motor recovery after contusion SCI. Exp Neurol. 2004;188:365–77.CrossRefPubMed
19.
go back to reference Ates O, Cayli SR, Gurses I, Turkoz Y, Tarim O, Cakir CO, et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci. 2007;14:658–65.CrossRefPubMed Ates O, Cayli SR, Gurses I, Turkoz Y, Tarim O, Cakir CO, et al. Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury. J Clin Neurosci. 2007;14:658–65.CrossRefPubMed
20.
go back to reference Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg Spine. 2001;94:245–56.CrossRef Schwartz G, Fehlings MG. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg Spine. 2001;94:245–56.CrossRef
21.
go back to reference Grossman RG, Fehlings MG, Frankowski RF, Burau KD, Chow DSL, Tator C, et al. A prospective, multicenter, Phase i matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma. 2014;31:239–55.CrossRefPubMedPubMedCentral Grossman RG, Fehlings MG, Frankowski RF, Burau KD, Chow DSL, Tator C, et al. A prospective, multicenter, Phase i matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma. 2014;31:239–55.CrossRefPubMedPubMedCentral
22.
go back to reference Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS, et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. J Neurosurg Spine. 2012;17:151–6.CrossRefPubMed Fehlings MG, Wilson JR, Frankowski RF, Toups EG, Aarabi B, Harrop JS, et al. Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial. J Neurosurg Spine. 2012;17:151–6.CrossRefPubMed
24.
go back to reference Steeves JD, Kramer JK, Fawcett JW, Cragg J, Lammertse DP, Blight AR, et al. Extent of spontaneous motor recovery after traumatic cervical sensorimotor complete spinal cord injury. Spinal Cord. 2011;49:257–65.CrossRefPubMed Steeves JD, Kramer JK, Fawcett JW, Cragg J, Lammertse DP, Blight AR, et al. Extent of spontaneous motor recovery after traumatic cervical sensorimotor complete spinal cord injury. Spinal Cord. 2011;49:257–65.CrossRefPubMed
Metadata
Title
The Effect of Non-Gabapentinoid Anticonvulsants on Sensorimotor Recovery After Human Spinal Cord Injury
Authors
Freda M. Warner
Catherine R. Jutzeler
Jacquelyn J. Cragg
Bobo Tong
Lukas Grassner
Frank Bradke
Fred Geisler
John K. Kramer
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 5/2019
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-019-00622-6

Other articles of this Issue 5/2019

CNS Drugs 5/2019 Go to the issue